DocumentRX-7650
Issued
Read4 min

Pfizer secures up to $1.5B for berobenatide trials

Up to $1.5 billion from Blackstone will fund trials of monthly-dosed berobenatide across obesity, knee osteoarthritis and sleep apnea, while Pfizer retains full control of the asset.

TAG T-8005 · 705 words on the filing

Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug Trials
Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug TrialsKost9n4 / pixabay

Summary of findings

  • Pfizer secured up to $1.5 billion from Blackstone Life Sciences for berobenatide trials.
  • Berobenatide is a monthly-dosed injectable GLP-1 formerly known as MET-097i at Metsera.
  • Pfizer says the berobenatide clinical program could grow to more than 20 trials.
  • Blackstone receives milestone payments but no drug rights; Pfizer retains full control.
  • Pfizer beat Novo to Metsera with a $10 billion offer about a year ago.

Pfizer secured up to $1.5 billion from Blackstone Life Sciences to fund clinical trials of berobenatide, the long-acting injectable GLP-1 candidate at the center of its cardiometabolic pipeline. The financing, announced after Wednesday’s market close, ties Blackstone’s recovery to regulatory and commercial milestones, although the payment schedule and amounts remain undisclosed.

Milestone payments could prove substantial given the size of the cardiometabolic disease market, but the deal included no forecast. Blackstone receives no rights to berobenatide; Pfizer retains full control of the asset and every decision concerning its clinical program.

What will the money test?

Pfizer says the berobenatide program could grow to more than 20 trials in obesity and related comorbidities, including knee osteoarthritis and obstructive sleep apnea. The company also says growing evidence supports developing the peptide as a monotherapy and in combinations with nutrient-stimulated hormone (NuSH) peptides, including analogs for amylin.

Amylin helps regulate blood sugar and appetite. The combination strategy could broaden the program, but the announcement supplied no trial identifiers, endpoints, start dates or comparative efficacy data.

The obesity portfolio also includes an oral GLP-1 drug that Pfizer acquired last year from Shanghai-based YaoPharma. The company gave no code name or development stage for that candidate in the financing announcement.

Why did Pfizer buy berobenatide?

Berobenatide was Metsera’s lead obesity candidate, where it carried the code name MET-097i. The long-acting injectable was designed for monthly dosing, making it attractive to Novo Nordisk as a potential successor to its weekly obesity drug, Wegovy.

Pfizer’s internal oral GLP-1 research had fallen short, prompting the company to seek external assets. About a year ago, Pfizer won the bidding contest with Novo through a $10 billion offer for Metsera.

That acquisition gave Pfizer control of the molecule; the Blackstone transaction adds development capital rather than another ownership step. Pfizer alone will decide how and when to run the planned studies.

What does Blackstone receive?

Funds managed by Blackstone Life Sciences will invest alongside funds managed by the firm’s perpetual private-equity strategy. If berobenatide achieves the agreed milestones, Blackstone will receive payments over a multi-year period.

Cecile Guegan, Pfizer’s chief financial officer and executive vice president, called the arrangement “a disciplined approach that pairs internal research investments with targeted investment from capital partners.” She added: “Today’s announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas.”

The announcement cited no berobenatide clinical results or detailed milestone economics. The $1.5 billion represents a ceiling rather than a guaranteed draw, while Blackstone’s future payment profile remains undefined.

What do competitors already have?

Novo Nordisk and Eli Lilly have converted obesity peptides into broader labels:

  • Novo’s Wegovy can treat the fatty liver disease MASH.
  • The Wegovy pill approval for weight management includes reducing the risk of major cardiovascular events.
  • Lilly’s Zepbound has added obstructive sleep apnea to its label.

Against that backdrop, Pfizer emphasizes berobenatide’s less burdensome monthly dosing. Lilly is pursuing a different proposition for next-generation metabolic medicines: better efficacy with retatrutide, a peptide engineered to activate the GLP-1, GIP and glucagon receptors.

Retatrutide sits in a broad clinical program evaluating obesity, type 2 diabetes and related disorders. Pfizer’s case for berobenatide remains less clinically documented, because its financing announcement provided no head-to-head efficacy or safety comparison.

Does this fit Blackstone’s playbook?

Blackstone has used similar financing structures elsewhere in biopharmaceuticals:

  • Earlier this year, the firm agreed to provide Apogee Therapeutics with up to $1.3 billion for late-stage development of a long-acting antibody for atopic dermatitis. Blackstone would receive royalties from an approved product; AbbVie subsequently acquired Apogee for about $11 billion.
  • Blackstone’s agreements with Moderna and Alnylam Pharmaceuticals leave the firm eligible for milestone payments and royalties.

The Pfizer transaction fits that capital-partner model, with one key difference: Blackstone finances the program without gaining rights to berobenatide. For Pfizer, the deal supplies outside funding for a candidate intended to anchor more than 20 studies. For Blackstone, the return still depends on berobenatide’s regulatory and commercial progress.

via businesswire.com (Original)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

10 articles

Linked filings

  1. K-2547
  2. K-8919
  3. K-1653
  4. K-4971
  5. P-2627